Follow-up to: Sertraline side effects
Question explored with the scientific record
Are there non-SSRI options with fewer or different risks?
The short version: non-SSRI options like tricyclics carry a different risk profile, but the evidence shows they are not safer—they trade one set of harms for another, and some risks are worse.
The evidence retrieved does not directly compare non-SSRI antidepressants to sertraline in a head-to-head trial. What it does show is that tricyclic antidepressants (TCAs) carry their own serious risks. A population-based study found TCA use was associated with a 2.1-fold increased risk of coronary heart disease events after adjusting for confounders [11]. TCAs also cause significant autonomic impairment compared to controls [13], and in vitro data shows they are directly neurotoxic to nerve cells at high concentrations [14]. The antimuscarinic (anticholinergic) effects are well-documented: amitriptyline, nortriptyline, and imipramine all block muscarinic receptors, causing dry mouth, constipation, blurred vision, and cognitive impairment [9]. In nursing home residents, both TCAs and SSRIs increased fall risk, with no clear safety advantage for either class [19].
The evidence on other non-SSRI options is thin. One study found that adding acupuncture to SSRI therapy improved response rates and reduced side effects compared to SSRIs alone [1], but that is an add-on, not a replacement. The post-SSRI sexual dysfunction survey [5] and the case report on venlafaxine withdrawal [6] confirm that non-SSRI serotonergic drugs carry their own discontinuation and sexual harm profiles.
| Risk | TCA evidence | SSRI evidence (from prior) |
|---|---|---|
| CHD events | 2.1x adjusted hazard ratio [11] | Not reported in retrieved evidence |
| Autonomic impairment | Significant vs controls [13] | Not directly compared |
| Neurotoxicity (in vitro) | Present at high concentrations [14] | Not studied |
| Fall risk (elderly) | Increased [19] | Increased [19] |
| Sexual dysfunction | Not reported in retrieved evidence | Documented, including persistent post-discontinuation [5] |
My call: non-SSRI options do not offer a clearly safer profile. TCAs add cardiovascular and anticholinergic risks that SSRIs do not carry. The evidence does not include a single trial comparing these classes head-to-head on hard outcomes like mortality or quality of life. Confidence: moderate for TCA risks, low for any comparative safety advantage.
Sources examined 19
-
Manual or electroacupuncture as an add-on therapy to SSRIs for depression: A randomized controlled trial
A large multicentre pragmatic randomized controlled trial showing that adding manual acupuncture or electroacupuncture to SSRI therapy in adults with moderate to severe depression improves response and remission rates, speeds up early improvement, reduces SSRI-related side effec…
DOI: 10.1016/j.jpsychires.2019.04.005 -
Sertraline for the treatment of depression in parkinson's disease
An open-label pilot study evaluating sertraline for depression in non-fluctuating Parkinson's disease found significant improvement in Beck Depression Inventory scores without changes in motor function or energy, though adverse effects were more common when combined with selegil…
DOI: 10.1002/mds.870120522 -
Un estudio multicéntrico doble ciego controlado con placebo de sertralina en el tratamiento agudo y de continuación de la depresión mayor
Sertraline demonstrates superior efficacy to placebo in the acute treatment (6 weeks) of major depressive disorder in outpatients, with higher response rates and lower discontinuation due to inefficacy; continuation among acute responders shows persistent improvement more often …
DOI: 10.1017/s1134066500002769 -
Serotonergic Antidepressants and Linezolid: A Retrospective Chart Review and Presentation of Cases
A retrospective chart review at a single center evaluating the safety of concomitant linezolid and serotonergic antidepressants in adults, identifying a rare case of serotonin syndrome and detailing two cases/circumstances related to the interaction.
DOI: 10.2190/PM.38.1.h -
Exposure to serotonin selective reuptake inhibitors or serotonin noradrenaline reuptake inhibitors and sexual dysfunction: Results from an online survey
An online survey of 135 adults with self-reported Post-SSRI Sexual Dysfunction (PSSD) characterizes demographic/clinical features, timing of symptom onset, and predictors of severe sexual dysfunction and poor wellbeing, suggesting an iatrogenic cascade rather than a true syndrom…
DOI: 10.3233/jrs-200074 -
Similar discontinuation symptoms for withdrawal from medium-dose paroxetine and venlafaxine after nine years in the same patient
A woman who developed a discontinuation syndrome after tapering paroxetine nine years earlier experienced the same symptoms, including a novel dry-eye symptom, when she occasionally missed doses of venlafaxine; symptoms resolved upon drug reinstatement, supporting a shared serot…
DOI: 10.1177/0269881107081562 -
Anticonvulsant hypersensitivity syndrome: cross-reactivity with tricyclic antidepressant agents
This study investigates the cross-reactivity between aromatic anticonvulsant agents and tricyclic antidepressants in patients with anticonvulsant hypersensitivity syndrome (AHS), revealing significant risks of recurrence upon exposure to tricyclic antidepressants.
DOI: 10.1016/s1081-1206(10)61103-9 -
The complex binding of tricyclic antidepressants to rat brain: The case of nortriptyline
This study characterizes the binding of [3H]nortriptyline to rat brain sections, revealing a complex binding pattern with high affinity to noradrenergic and serotonergic terminals, which may explain the diverse effects of tricyclic antidepressants.
DOI: 10.1016/0006-8993(84)90191-4 -
Tricyclic antidepressants as antimuscarinic drugs: In vivo and in vitro studies
This study investigates the antimuscarinic properties of tricyclic antidepressants (nortriptyline, amitriptyline, and imipramine) through in vivo and in vitro experiments, revealing their relative potencies and mechanisms of action compared to scopolamine.
DOI: 10.1016/0006-2952(77)90069-7 -
Selected Tricyclic Antidepressant Ingestions Involving Children 6 Years Old or Less
A retrospective study of 48 pediatric patients (≤6 years) with tricyclic antidepressant ingestions at a Long Island poison control center (1993–1997) found that most exposures were asymptomatic at doses <5 mg/kg, with limited need for hospital-based management, suggesting home o…
DOI: 10.1111/j.1553-2712.2001.tb01278.x -
Exposure to tricyclic antidepressants is associated with an increased risk of incident CHD events in a population-based study
This study investigates the association between tricyclic antidepressant use and the risk of incident coronary heart disease (CHD) events over a 10-year follow-up in a population-based cohort of Nova Scotians aged 45 and older.
DOI: 10.1016/j.ijcard.2009.06.036 -
Time‐dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants
This study investigates the time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants, revealing that while these drugs can inhibit recombinant CYP enzymes, their effect on human liver microsomal CYP enzymes is minimal.
DOI: 10.1111/j.1365-2125.2007.02964.x -
Neurophysiologic Tests during Antidepressive Treatment - an Exploratory Study
This exploratory study investigates the sensitivity of neurophysiological parameters to autonomic side effects in patients undergoing treatment with tricyclic antidepressants (TCA) and serotonin-reuptake inhibitors (SSRI), revealing significant autonomic impairments associated w…
DOI: 10.1055/s-2000-8354 -
Differential neurotoxicity of tricyclic antidepressants and novel derivatives in vitro in a dorsal root ganglion cell culture model*
This study investigates the differential neurotoxicity of tricyclic antidepressants and their novel derivatives in vitro using a dorsal root ganglion cell culture model, revealing significant variations in neurotoxic potential among the compounds tested.
DOI: 10.1017/S0265021507000154 -
Phenytoin: Similarity to tricyclic antidepressants
This study investigates the discriminative stimulus properties of phenytoin in rats, comparing its effects to those of various tricyclic antidepressants, and establishes a dose-response relationship for phenytoin's discriminative effects.
DOI: 10.1016/0091-3057(83)90111-9 -
Monitoring of tricyclic antidepressants in human serum and plasma by HPLC: characterization of a simple, laboratory developed method via external quality assessment
This study presents a laboratory-developed reversed-phase high-performance liquid chromatography (HPLC) method for monitoring tricyclic antidepressants in human serum and plasma, demonstrating its effectiveness through external quality assessment over three years.
DOI: 10.1016/s0731-7085(98)00263-5 -
Sodium lactate infusions after treatment with tricyclic antidepressants: Behavioral and physiological findings
This study investigates the effects of sodium lactate infusions on patients with panic disorder before and after treatment with tricyclic antidepressants, finding a significant reduction in panic attacks and anxiety measures post-treatment.
DOI: 10.1016/0006-3223(88)90252-1 -
A Separation Study of Tricyclic Antidepressant Drugs by HPLC with β-Cyclodextrin Bonded Stationary Phase
This study presents a systematic investigation of the separation of tricyclic antidepressant drugs using reversed phase HPLC with β-cyclodextrin bonded stationary phase, examining the effects of organic modifier content and pH on retention and deriving experimental equations for…
DOI: 10.1080/10826079308019703 -
Antidepressants and the Risk of Falls among Nursing Home Residents
This study investigates the association between the use of different classes of antidepressants and the risk of falls among nursing home residents, finding that both tricyclic antidepressants and selective serotonin-reuptake inhibitors are linked to increased fall rates.
DOI: 10.1056/nejm199809243391303